

SUMMARY OF PRODUCT CHARACTERISTICS (SmPC)

1. NAME OF THE MEDICINAL PRODUCT:

Typhoid Vi Conjugate Vaccine

Strength: Each 0.5 mL of dose contains:

Purified Vi-Capsular Polysaccharide of *S. typhi* Ty2 conjugated to Tetanus Toxoid: 25 µg

Pharmaceutical Form: Sterile Solution for Injection

2. QUALITATIVE AND QUANTITATIVE COMPOSITION:

a). Composition for single dose presentation in vial

Each dose of 0.5 mL contains:

Purified Vi-Capsular Polysaccharide of <i>S. typhi</i> Ty2 conjugated to Tetanus Toxoid	25 µg
Sodium chloride IP	4.5mg
Water for injection IP	q.s. to 0.5mL

b). Composition for Multi-Dose presentation in vial

Each dose of 0.5 mL contains:

Purified Vi-Capsular Polysaccharide of <i>S. typhi</i> Ty2 conjugated to Tetanus Toxoid	25 µg
Sodium chloride IP	4.5mg
2- Phenoxyethanol IP	5.0 mg
Water for injection IP	q.s. to 0.5mL

3. PHARMACEUTICAL FORM (DOSAGE FORM AND STRENGTH)

Sterile Solution for Injection

4. CLINICAL PARTICULARS

4.1. Therapeutic indications

Typbar TCV[®] is indicated in infants, children and adults (≥ 6 months to ≤ 65 year age group) for active immunization against *Salmonella* Typhi infection.

4.2. Posology and method of administration

Inject 0.5 mL intramuscularly.


Single dose: 1 dose (0.5mL) in ≥ 6 months to ≤ 65 years age group

Typbar TCV[®] should be given intramuscularly in the vastuslateralis (anterolateral aspect of thigh) in infants < 12 months of age or in the deltoid (upper arm) muscle in children ≥ 12 months of age.

Typbar TCV[®] should not be injected into the gluteal area or areas where there may be a nerve trunk.

PFS Handling procedure: Prior to administration, ensure that the plunger rod is firmly attached to the rubber stopper by turning the plunger rod clockwise until slight resistance is felt. Do not over tighten. Remove rubber tip-cap from the syringe and fix the needle on syringe by turning in clock wise direction into Luer-lock until it is securely fixed to the syringe, remove the needle cap before injecting. Do not rotate Luer-lock. Finger grip with back stopper will prevent plunger rod coming out from the syringe barrel. Do not remove the back-stopper from the syringe.

“Do not remove the back stopper from the syringe”



4.3 Contraindications

Hypersensitivity to any constituent of the vaccine.

4.4 Special warnings and precautions for use:

- Do not administer intravenously, intradermally, or subcutaneously
- Like all other vaccines, supervision and appropriate medical treatment should always be available to treat any anaphylactic reactions following immunization.
- During fever or severe infection. • Epinephrine injection (1:1000) must be immediately available in case of an acute anaphylactic reaction or any allergic reaction that occurs due to any component of the vaccine.

4.5 Interaction with other medicinal products and other forms of interaction (Drug Interaction):

Typbar-TCV[®] should not be mixed with any other vaccine or medicinal product, because the interactions with other vaccines or medical products have not been established.

Typbar TCV[®] was proven to not interfere in terms of immunogenicity and safety with the Measles-Mumps-Rubella (MMR), measles-rubella (MR), Yellow fever (YR), and Meningococcal Conjugate Vaccine (MCV-A) when they co-administered.

4.6 Use in Special populations (such as pregnant women, lactating women, paediatric patients, geriatric patients etc.) (Pregnancy and Lactation):

Safety and effectiveness have not been established in pregnant women and in nursing mothers.

4.7 Effect on ability to drive and use machines:

No studies on the effect of **Typbar-TCV[®]** on the ability to drive and use machines have been performed.

4.8 Undesirable Effects:

Clinical Trial Experience

The safety of **Typbar-TCV[®]** vaccine was established in phase II and III clinical trials.

In a phase II study conducted in India among 100 children aged 2-17 years, no significant adverse events were demonstrated to be associated with the vaccine. Commonly reported adverse events included pain and swelling at injection site, fever and headache.

In the larger phase III study, a total of 981 healthy subjects were enrolled into the study at 8 clinical sites into 2 study cohorts. A single arm, open label cohort enrolled 327 subjects between the ages of ≥ 6 months to 2 years to receive a single dose of **Typbar-TCV[®]**. A second randomized controlled arm recruited 654 subjects between the age > 2 years to 45 years, allocated equally to receive a single dose of either **Typbar-TCV[®]** or a comparator Vi polysaccharide vaccine.

The most common general and local adverse events were fever (4-10%) and pain (3-4%) and swelling (1-2%) at injection site, post vaccination. All these events were resolved within 48 hours with symptomatic treatment. Uncommon adverse events observed were tenderness, and erythema at injection site, arthralgia, malaise and myalgia. No differences were observed in the adverse events reported between plain Vi polysaccharide and **Typbar-TCV[®]**. The adverse events reported were similar in nature as reported with other commercial Vi vaccines. No vaccine-related serious adverse events (SAEs) were reported in the clinical trial.

Post-Marketing Experience

Post Marketing Surveillance – Active and Passive surveillance was conducted in approximately 10000 vaccine recipients of **Typbar TCV[®]**.

Active surveillance was performed by physicians provided with PMS forms to report any observed adverse events. Passive surveillance was performed by voluntary reporting of adverse events by pediatricians/physicians across India. The adverse reactions observed in the PMS study were ranked under headings of frequency of occurrence using the following convention:

Very common: $\geq 10\%$

Common: $\geq 1\%$ and $< 10\%$

Uncommon: $\geq 0.1\%$ and $< 1\%$

Rare: $\geq 0.01\%$ and $< 0.1\%$

Very rare: $< 0.01\%$

Fever, pain and swelling at injection site, pruritus/itching were common, whereas cough and cold are uncommon. Persistent crying, rash, generalized tonic-clonic seizure (GTCS), chills and rigors were rare. The above events were reported from the post marketing surveillance study and it is not always possible to establish a causal relationship of these events to the product.

4.8.1 Immune Response

4.8.1.1 Phase 3 clinical study

The phase 3 clinical trial that enrolled 981 healthy subjects into the trial across two age cohorts had 654 subjects aged >2 to <45 years (RCT) received a single dose of **Typbar TCV[®]** or Vi Polysaccharide vaccine and other 327 subjects aged >6 months to <2 years (OLT) received a single dose of **Typbar TCV[®]** vaccine only.

After a single dose of the vaccine, seroconversion (≥ 4 -fold increase of anti-ViIgG antibodies) at 6 weeks post-vaccination in subjects aged 6 months to <2 years, >2 to <5 years, >5 to <15 years and >15 to <45 years was 98.1%, 99%, 99.3% and 91.9%, respectively.

Subjects were followed up for long term immunogenicity for a period of 3 and 5 years post-vaccination. Seroconversion rates (% with ≥ 4 -fold increase in anti-Vi titer over baseline at day 0) of **Typbar TCV[®]** subjects at 3 and 5 years after vaccination in the RCT group (>2 to <45 years) remained to be high at 76.6% and 70.4% respectively. Similarly in the OLT (>6 months to <2 years), ≥ 4 -fold seroconversion rates of **Typbar TCV[®]** subjects at 3 and 5 years after vaccination are 78.1% and 76.6% respectively.

Sero Efficacy study:

University of Oxford, U.K, estimated the seroefficacy of **Typbar TCV[®]** vaccine as 85% and showed that **Typbar TCV[®]** substantially reduces the number of serologically defined clinical or subclinical infections in infants, children, and adults compared to the Vi-PS vaccine.

4.8.1.2 Phase 4 Clinical Studies

TCV Measles non-interference study:

In a Phase 4 TCV Measles non-interference study, a total of 500 healthy infants of age group of 8 to 10 months were enrolled in this study.

Group 1: **Typbar TCV[®]** & Measles co-administration at 9 months.

Group 2: Measles at 9 months and **Typbar TCV[®]** at 10 months.

Group 3: **Typbar TCV[®]** at 8 months and Measles at 9 months.

Group 4: Only Measles at 9 months.

MMR vaccine was administered to all 4 groups at 15 months of age.

Antibody responses to **Typbar TCV[®]** and Measles in terms of GMT and 4-fold seroconversion on day 28 post-vaccination were higher in Group 1 as compared to Groups 2, 3 and 4. The above results indicate that concomitant administration of **Typbar TCV[®]** and measles-containing

vaccine/MMR does not influence the antibody titers either way and that the titers are higher in the groups where concomitant administration of TCV and Measles was done. The safety profiles for each vaccination regimen were comparable and clinically acceptable. Based on the immunogenicity results, Concomitant administration of **Typbar TCV[®]** and Measles at 9 months of age revealed that the immune responses with respect to each antigen (i.e., Anti Vi IgG and Anti-measles IgG titers in terms of GMT and 4-fold seroconversion) was non-inferior to the responses seen when the vaccines are administered alone. The immunogenicity data support the concomitant administration of measles-containing vaccine/MMR with **Typbar TCV[®]**.

Typbar TCV meningococcal type-A non-interference study:

In a Phase 2b study in Burkina Faso, participants aged around 9 months old were co-administered the vaccines Typbar TCV[®], MR and YR vaccines. A total of 100 participants were enrolled and randomized to receive either Typbar TCV or IPV along with MR and YR vaccines.

Group 1: Typbar TCV[®], MR and YR are co-administered.

Group 2: IPV, MR and YR are co-administered.

The results indicated that the Typbar TCV vaccine can be co-administered with MR and YR vaccines without any safety or immunogenicity interference concerns.

Typbar TCV[®] & Measles co-administration at 9 months.

In Burkina Faso, a double-blinded, randomized controlled trial was done to assess the safety and immunogenicity in children aged 15-23 months. In this study meningococcal type-A and measles-rubella vaccine is co-administered with typhoid conjugate. A total of 150 children were recruited and vaccinated and these 150 participants were divided into three groups.

Group 1: Typbar TCV[®], IPV and MR are co-administered.

Group 2: Typbar TCV[®], MR and MCV-A are co-administered.

Group 3: IPV, MR and MCV-A are Co-administered.

The results show that TCV can be safely co-administered at 15 months with MCV-A without interference. This novel study on the co-administration of TCV with MCV-A provides data to support large-scale uptake in sub-Saharan Africa.

Typbar TCV[®] comparator study:

In the comparator phase 4 study (340 subjects), non-inferiority in the immune response of Typbar-TCV[®] as compared to Typhim Vi[®] has been examined. While safety profile of Typbar-TCV[®] is comparable to that of a WHO-prequalified typhoid vaccine – Typhim Vi[®], its immune response, as measured by anti-Vi IgG titers—28 days post vaccination, is non-inferior to Typhim Vi[®] vaccine.

Typbar TCV[®] safety & immunogenicity in older adults:

The phase 4 clinical trial that enrolled 300 healthy subjects into the trial across two age cohorts had 100 subjects aged >18 to <45 years (cohort 1) and other 200 subjects aged >45 years to <65 years (cohort 2) received a single dose of **Typbar TCV[®]** vaccine. After a single dose of the vaccine, Geometric mean titers of anti-Vi IgG antibody at pre- and post-vaccination in cohort 1 subjects were 12 EU/mL, 1468.81 EU/mL and in cohort 2 subjects were 13.01 EU/mL, 1568.22 EU/mL respectively. The results indicating that the Typbar TCV[®] is safe and equally immunogenic in older adults.

4.8.1.3 A Phase 2b Human Challenge Study

A Phase 2b Human Challenge study was conducted at Oxford University, UK using controlled human infection model of *Salmonella* Typhi. A total of 112 participants were randomly assigned (1:1:1) to receive a single parenteral dose of **Typbar TCV[®]**, Vi-PS-Typhim Vi, or control, meningococcal ACWY-CRM conjugate vaccine. About 1-month post-vaccination, participants were challenged orally with $1-5 \times 10^4$ colony forming units (CFUs) of *S Typhi* Quail's strain. The participants were followed up for a 2-week period post challenge for diagnosis of Typhoid fever. When an approximate field definition of typhoid fever was applied, such as fever $\geq 38.0^\circ\text{C}$ followed by bacteraemia, the estimated vaccine efficacy of **Typbar TCV[®]** was 87.1% as compared to 52.3% in TyphimVi[®] group. Four-fold Seroconversion rate of **Typbar TCV[®]** was 100% compared to 88.6 % for Typhim Vi[®].

4.8.1.4 Efficacy and Effectiveness Studies Across the Globe

Efficacy and effectiveness studies are conducting in several countries, such as Nepal, Bangladesh, Burkina Faso, Malawi, India and Pakistan.

Nepal: A randomised controlled trial was conducted in Nepal to assess safety and efficacy of TCV in children from 9 months to 15 years of age, in which participants were randomised 1:1 to TCV or a capsular group A meningococcal vaccine. Approximately 20,000 children living in the Lalitpur district within Kathmandu valley, were enrolled in the study, and followed to measure both safety and efficacy data, which will include adverse events, hospitalisations, antibiotic use, and fever frequency. Typbar TCV[®] vaccine is found to be safe and well tolerated with 81.6% vaccine efficacy.

Pakistan: Pakistan is facing the world's largest outbreak of extensively drug-resistant (XDR) Typhoid. Vaccination campaign for children aged 6 months to 10 years old with Typhoid Conjugate Vaccine (**Typbar-TCV[®]**) was conducted in high-risk areas of Hyderabad during 2018. About 207,000 children were vaccinated. Fever was followed by local reactogenicity 144/207,000 (1.89%). No serious AEFI was observed. Administration of a single dose of **Typbar-TCV[®]** among children aged 6 months to 10 years old during an outbreak setting of Hyderabad Pakistan was safe. At the same time as the campaign, researchers set up a surveillance system in the same area over an 18-month period to screen a cohort of over 20,000 children, who received the vaccine, to detect cases of typhoid. They found that 9 out of 10 children in the cohort, or 89%, did not contract the disease.

India: The Navi Mumbai Municipal Corporation (NMMC), India took a landmark decision to be the first in the world to introduce Typhoid Conjugate Vaccine (**Typbar TCV[®]**) into its immunization program, in two phases. This campaign marked the first public-sector introduction of TCV globally and aimed to vaccinate approximately 390,000 children aged 9 months to under 15 years. The events will be reported through the routine AEFI surveillance and active phone follow-ups.

Malawi: The TyVac conducted a phase 3 randomized, blinded, controlled clinical efficacy trial of typhoid Vi-capsular conjugate vaccine in Malawian children ages 9 months to 12 years. Participants were randomized in a 1:1 ratio to receive either typhoid Vi-capsular conjugate vaccine or meningococcal serogroup A conjugate vaccine. The subset of 200 children aged 9-11 months received typhoid Vi-capsular conjugate vaccine co-administered with measles-rubella vaccine at a different anatomic site. It was reported that **Typbar TCV[®]** vaccine is highly immunogenic (~500-fold increase from baseline titer) and non-interferes with the Measles vaccine.

Burkina Faso: A double-blinded, randomized controlled trial was done to assess the safety and immunogenicity in children aged 15-23 months. In this study meningococcal type-A and measles-rubella vaccine is co-administered with typhoid conjugate. The study was conducted in 150 children and the results show that TCV can be safely co-administered at 15 months with MCV-A without interference. This novel study on the co-administration of TCV with MCV-A provides data to support large-scale uptake in sub-Saharan Africa.

Bangladesh: A observer-blinded, cluster-randomized, controlled trial with 2 years follow-up to assess the protective impact of the Vi-TCV vaccine in children aged 9 months to <16 years. Approximately, 32500 participants were enrolled and in that >4800 participants had AEs assessed at 1 week following vaccination. Mild fever was the most common AE in both vaccine groups.

WHO SAGE Noted:

SAGE re-emphasized the importance of programmatic use of typhoid vaccines for controlling endemic disease. Following review of results from different clinical trials of **Typbar TCV[®]** and other similar typhoid conjugate vaccines, SAGE recommended the introduction of Typhoid Conjugate Vaccine for infants and children over 6 months of age as a single dose in typhoid endemic countries. Routine programmatic administration of TCV is likely to be most feasible at existing vaccine visits at 9 months (Co-administration of measles and measles-mumps-rubella vaccines) of age or in the second year of life.

Introduction of Typhoid Conjugate Vaccine should first be prioritized for countries with the highest burden of disease or a high burden of antibiotic resistant *Salmonella* Typhi. Reviewing epidemiological and modelling data, SAGE and GACVS recommended catch-up vaccination when feasible, with priority for catch up in the youngest age groups (up to 15 years of age), noting that the burden of disease and programmatic feasibility are greater in this age range than in adults.

Weekly Epidemiological Record, No 48, 1st December 2017 and WHO Weekly Epidemiological Record on 25 January 2019 (Extract from report of GACVS meeting of 5-6 December 2018)

4.9 Overdose:

No case of overdose has been reported.

5. PHARMACOLOGICAL PROPERTIES

5.1 Mechanism of Action:

Typbar TCV[®] is a vaccine containing polysaccharide of *Salmonella* Typhi Ty2 conjugated to Tetanus Toxoid. Vi-Capsular polysaccharide of *Salmonella* Typhi alone elicit B-cell responses, but the conjugation of bacterial polysaccharide to a protein carrier provides foreign peptide antigens that are presented to the immune system eliciting antigen-specific CD4⁺ Th cells, referred to as T-dependent antibody responses. The T-dependent responses, which are elicited by toxoids, induce both higher-affinity antibodies and long-term immune memory.

5.2 Pharmacodynamic properties

Typbar TCV[®] vaccine was evaluated in a pivotal Phase 3 study for its safety and immunogenicity in healthy Indian participants aged 6 months to 45. From this study, which is the largest clinical trial conducted thus far, results established that the vaccine is safe and immunogenic. Typbar TCV[®] vaccine is the only typhoid conjugate vaccine followed for persistence and has proven safe and immunogenic even after 7 years post-vaccination. Later on, a Phase 4 study was conducted and found that the vaccine is safe and induces a similar immune response in elderly adults aged between 45- 65 years. In another Phase 4 study, Typbar TCV[®] was proven for its non-interference with the MMR vaccine when co-administered in children ages 10 months. Typbar TCV[®] also proven to be safely co-administered with meningococcal conjugate vaccine (MCV-A), measles-rubella (MR), and yellow fever (YF) vaccines without interference in African children.

Regarding vaccine efficacy, BBIL collaborated with Oxford University, evaluated the protective efficacy in a human challenge study, and reported 87.1% efficacy against typhoid infection. Typbar TCV[®] vaccine safety was assessed in ~9000 participants and found to be safe, and no vaccine-related SAEs were reported.

TyVAC conducted several clinical trials in various countries with endemic background to evaluate the efficacy, effectiveness and non-interference of the Typbar TCV[®] vaccine. The results were reported that the vaccine has shown more than 80% efficacy in endemic countries such as Nepal, Malawi, Zimbabwe and Bangladesh. A mass vaccination programme was conducted in Pakistan where the emergence of superbug, extensively drug-resistant (XDR) typhoid cases were reported. Approximately 207,000 children were vaccinated with Typbar TCV[®] in high-risk areas, and found that the vaccine has shown 95% efficacy against XDR typhoid infection

5.3 Pharmacokinetic properties

Evaluation of pharmacokinetic properties is not required for vaccines.

6. PRECLINICAL SAFETY DATA (NON-CLINICAL PROPERTIES)

6.1 Animal Toxicology or Pharmacology

Non-clinical toxicity studies with **Typbar TCV[®]** were conducted in Rabbits and Mice. Single dose and repeat dose toxicity studies were conducted in mice and rabbit to evaluate the safety and tolerability of the Typhoid Vi capsular Polysaccharide Tetanus Toxoid Conjugate Vaccine (**Typbar TCV[®]**). The results of the studies reported that there were no immediate hypersensitivity or anaphylactic reactions in the Test and Control groups. No premature deaths and clinical observation of acute toxicity or abnormalities were detected in the test group compared to the control.

7. DESCRIPTION:

Clear to slightly turbid liquid.

8. PHARMACEUTICAL PARTICULARS

8.1 List of excipients

Sodium chloride

2-Phenoxyethanol (in multi-dose presentation)

8.2 Incompatibilities

This medical product must not be mixed with other medicinal products.

8.3 Shelf life

The expiry date of the vaccine is indicated on the label and carton of the product.

9. NATURE AND CONTENTS OF CONTAINER (PACKAGING INFORMATION)

Typbar TCV[®] is presented in USP Type 1 glass vial and Pre-Filled Syringe (PFS)

Single Dose PFS : 0.5mL

Single Dose Vial : 0.5 mL

Multi Dose Vial : 2.5 mL

9.1 Storage and Handling Instructions

9.1.1 Special Precautions for Storage


Store at +2°C to +8°C. Do not freeze. Discard if frozen. Shake well before use. Keep out of reach of children. Do not use the vaccine after the expiration date shown on the label. For multi dose vials use different syringe each time to vaccinate. After first opening, the vaccine can be used for up to 28 days provided.

- It is stored between 2°C - 8°C

- It is NOT delivered in a Controlled Temperature Chain (CTC) programme. Should this be the case, the vaccine should be discarded after 6 hours or at the end of the session, whichever occurs first.

The Vaccine Vial Monitor

Vaccine Vial Monitor (VVM30) are on the cap of **Typbar TCV[®]** Vials supplied through Bharat Biotech. VVM30 are supplied by TEMPTIME Corporation, USA. The colour dot which appears on the cap is a VVM30. This is a time-temperature sensitive dot that provides an indication of the cumulative heat to which the vial has been exposed. It warns the end user when exposure to heat is likely to have degraded the vaccine beyond an acceptable level.



Stability under Extended Controlled Temperature Conditions (WHO-ECTC guidelines)

This vaccine has been proven to remain stable for use beyond the traditional +2°C to +8°C cold chain under monitored conditions in keeping with the CTC, as defined by the World Health Organization. If an immunization programme decides it is advantageous to apply a CTC strategy to delivery of this vaccine, it may do so according to one of the following two options: (a) removal from the traditional +2°C to +8°C cold chain for up to THREE consecutive days just prior to administration, when stored or transported at temperatures not exceeding 55°C ; or (b) removal from the traditional +2°C to +8°C cold chain for up to SEVEN consecutive days just prior to administration, when stored or transported at temperatures not exceeding 40°C. Once unopened

vaccine vials are brought into either of these CTC scenarios, they must be used within the selected and tracked CTC time frame or appropriately discarded. All vials opened during an immunization session must be discarded after 6 hours or at the end of the session, whichever occurs first. The WHO recommends the use of an additional peak temperature threshold indicator to monitor that vaccines are not exposed to temperatures above the permitted threshold. Additional guidance on implementing a CTC delivery strategy is available from the World Health Organization.

9.2 Special precautions for disposal

Any unused product or waste material should be disposed of in accordance with local requirements.

10. PATIENT COUNSELLING INFORMATION

Prior to the administration of this vaccine, the healthcare professional should enquire and inform the individual and/or his parents/guardians of the following:

1. Enquire about any previous or known history of severe hypersensitivity to any component of Typbar TCV[®] or life-threatening reactions after the previous administration of any vaccine.
2. Enquire about any fever, febrile illness, or immunocompromised condition that may alter the response to Typbar TCV[®]. In this case, the immunization can be postponed until the condition is resolved.
3. Enquire about any history of bleeding disorders as in the case of all invasive interventions such as intramuscular injections.
4. Enquire and Inform that the antibody response in persons with endogenous or iatrogenic immunosuppression may be insufficient, and a protective immune response may not be elicited in all vaccine recipients.
5. Vaccinated persons and their parent(s)/guardian(s) should be informed that the most common general and local adverse events of Typbar TCV[®] were fever (4-10%), pain (3-4%), and swelling (1-2%) at the injection site post-vaccination. All these events were resolved within 48 hours with symptomatic treatment. Uncommon adverse events observed were tenderness and erythema at the injection site, arthralgia, malaise, and myalgia.
- 6.. Instruct vaccine recipients and their parent(s)/guardian(s) to report any adverse reactions if encountered to their healthcare provider and/or report by calling 1-800-102-2245 (Toll-free number) or emailing feedback@bharatbiotech.com.

11. MARKETING AUTHORISATION HOLDER (DETAILS OF MANUFACTURER)

Manufactured by



Bharat Biotech International Limited

Sy. No. 230, 231 & 235, Genome Valley,

Turkapally, Shamirpet Mandal,

Medchal, Malkajgiri District, Telangana State, India, Pin: 500078.

Email: feedback@bharatbiotech.com

Toll free number: 1800 102 2245

12. DETAILS OF MARKETING AUTHORISATION NUMBER(S) (DETAILS OF PERMISSION OR LICENSE NUMBER WITH DATE)

MF-244/2012

DATE OF FIRST MARKETING AUTHORISATION

02 DEC 2012

13. DATE OF REVISION